Search

Your search keyword '"Sugimoto, Danny"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Sugimoto, Danny" Remove constraint Author: "Sugimoto, Danny"
34 results on '"Sugimoto, Danny"'

Search Results

1. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

2. Risk of COVID-19 after natural infection or vaccination

3. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study

4. Risk of COVID-19 after natural infection or vaccination

6. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension

10. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

17. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study

18. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

24. Abstract #239 Insulin Degludec/Liraglutide (Ideglira) Achieved Non-Inferior A1c Reduction; Weight Loss and Fewer Hypoglycemic Episodes while Using a Simple Regimen with Fewer Injections and Dose Adjustments Compared with Basal–Bolus Therapy: An Analysis of Dual VII

25. Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)

26. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension

27. The TRINITY Study: distribution of systolic blood pressure reductions

30. The TRINITY Study: distribution of systolic blood pressure reductions.

31. 1003-P: Clinical Response (HbA1c ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1c and Body Weight in the SUSTAIN Program.

33. Empagliflozin in Patients with Chronic Kidney Disease

34. A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.

Catalog

Books, media, physical & digital resources